Influence
July 8, 2020

Regenstrief research scientists part of leadership for American Delirium Society Digital Meeting

Dr. Noll Campbell, Dr. Babar Khan, and Dr. Sikandar Khan man “mission control” during the meeting.

The COVID-19 pandemic has posed many challenges for conference organizers around the world. Two Regenstrief Institute research scientists successfully adjusted the American Delirium Society (ADS) conference from in-person to virtual and attracted more than 400 registrations from around the world.

The digital meeting was co-chaired by Indiana University Center for Aging Research at Regenstrief Institute Associate Director Babar Khan, M.D., M.S., and Regenstrief research scientist Noll Campbell, PharmD, M.S. Dr. Khan was the 2019-2020 president of the ADS, and Dr. Campbell is the ADS treasurer.

Regenstrief research scientist Sikandar Khan, D.O., and Indiana University School of Medicine administrative coordinator Makenna Flory assisted with managing the technology during the presentations.

The digital meeting featured about three dozen experts discussing the latest delirium-related research. The ADS works to lead the effort to foster research, education, quality improvement, advocacy and implementation science to minimize the impact of delirium on the health and wellbeing of patients.

Regenstrief researchers are pioneers in the field of delirium and have played an important role in the diagnosis and treatment of ADS. Regenstrief scientist Malaz Boustani, M.D., MPH, was the founding president of the organization.

The next meeting will take place in Indianapolis in March 2021.

Related News

Rachel Patzer, PhD

Factors Affecting Treatment Selection Among Patients With Hidradenitis Suppurativa

Published in JAMA Dermatology. Here is a link to the article.   Regenstrief Institute authors:  Rachel Patzer, PhD, MPH

Thomas Imperiale

Next generation stool DNA test has best detection rate of noninvasive colorectal cancer screening tools

Study of highly sensitive noninvasive test published in New England Journal of Medicine A study of more than 21,000

Rachel Patzer, PhD, MPH and Kalli Koukounas, MPH

JAMA study finds facilities treating poor patients penalized by CMS payment model

Social risk and treatment for end-stage kidney disease A new study of more than 2,000 dialysis facilities randomized to